For Immediate Release: 11/26/2009

Millipore and Affomix Announce Technology Evaluation Agreement

Affomix will use proprietary technology to produce highly specific recombinant antibodies against challenging targets selected by Millipore

Billerica, MA and Branford, CT - Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced it has signed a commercial agreement to evaluate Affomix’s Y2HExpress™ technology. Affomix is a pioneer in the development of automated, high-throughput recombinant monoclonal antibody selection technology.

Under the terms of the agreement Affomix will generate antibodies against a number of challenging targets selected by Millipore. Affomix will utilize its Y2HExpress™ technology that provides an automated approach to the selection of single-chain antibodies (scFvs) with substantially increased throughput, and specificity, over conventional yeast two hybrid (Y2H) and alternative antibody selection methodologies. Financial terms of the agreement were not disclosed.  

“Millipore is continuously evaluating promising technologies that will provide our customers with an advantage in their protein characterization studies,” said Sallie Cassel, Director of Marketing for Antibodies and Immunoassays at Millipore. “Y2HExpress™ has the potential to provide customized recombinant antibodies against targets at an unprecedented rate and level of specificity,” Cassel explained.

“Affomix is pleased to be working with an internationally renowned company such as Millipore,” said John Boyce, Co-Head of Business Development for Affomix, and Co-Founder of Delphi Bio. “Our proprietary technologies are designed to revolutionize antibody selection, protein detection and quantitation. This combination has the potential to complement Millipore’s impressive offering of native antibodies by providing their customers with a broad selection of highly specific recombinant antibodies ” Boyce continued.

About Millipore

Millipore is a life science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees in 30 countries worldwide.

Advancing Life Science Together™

Research. Development. Production.

About Affomix - Affomix is an emerging leader in the antibody technology space, with high throughput methodologies to select, at an unprecedented rate, against native epitopes as well as post-translationally modified proteins. These proprietary technologies will allow the company to achieve its ultimate objective of generating the human Affome^TM, a comprehensive set of antibodies that can be used to detect and quantify all proteins in the human proteome.

Utilizing these and other proprietary technologies, Affomix is positioned to commercialize and enable the commercialization of products that are at the convergence of genomics and proteomics.

Forward-Looking Statements - Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.